Baptist Health South Florida
This research study will evaluate how well brain metastases associated with HER-2 positive breast cancer can be controlled using a type of radiation known as stereotactic radiosurgery (SRS) when combined with three therapeutic agents, tucatinib, capecitabine, and trastuzumab. The combined use of SRS with the three drugs is considered investigational.
Brain Metastases
HER2-positive Breast Cancer
Combined use of SRS with Tucatinib, Trastuzumab, and Capecitabine
Phase 1
Study Type : | Interventional |
Estimated Enrollment : | 40 participants |
Masking : | None (Open Label) |
Primary Purpose : | Treatment |
Official Title : | Phase 1 Trial of Tucatinib, Trastuzumab, and Capecitabine With Stereotactic Radiosurgery (SRS) in Patients With Brain Metastases From HER-2 Positive Breast Cancer |
Actual Study Start Date : | September 18, 2023 |
Estimated Primary Completion Date : | November 1, 2024 |
Estimated Study Completion Date : | November 1, 2025 |
Arm | Intervention/treatment |
---|---|
Experimental: Investigational Treatment |
Combination Product: Combined use of SRS with Tucatinib, Trastuzumab, and Capecitabine |
Ages Eligible for Study: | 18 Years |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Recruiting
Miami Cancer Institute at Baptist Health, Inc.
Miami, florida, United States, 33176